Gossamer Bio (NASDAQ:GOSS) Rating Lowered to Neutral at Wedbush

Gossamer Bio (NASDAQ:GOSS) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a note issued to investors on Tuesday, MarketBeat reports. They currently have a $1.00 target price on the stock, down from their previous target price of $6.00. Wedbush’s target price points to a potential upside of 138.10% from the company’s current price.

Several other brokerages also recently commented on GOSS. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a report on Thursday, January 22nd. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. Leerink Partners downgraded shares of Gossamer Bio to a “market perform” rating in a research note on Tuesday. Finally, Barclays downgraded shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a research note on Tuesday. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.67.

Gossamer Bio Trading Down 80.3%

GOSS stock opened at $0.42 on Tuesday. Gossamer Bio has a 12-month low of $0.33 and a 12-month high of $3.87. The business’s 50-day moving average is $2.66 and its 200 day moving average is $2.68. The stock has a market cap of $97.21 million, a price-to-earnings ratio of -0.61 and a beta of 1.93.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. MMA Asset Management LLC purchased a new stake in Gossamer Bio in the 4th quarter worth about $31,000. Soltis Investment Advisors LLC purchased a new stake in shares of Gossamer Bio in the fourth quarter worth approximately $31,000. Ciovacco Capital Management LLC acquired a new stake in shares of Gossamer Bio during the third quarter worth approximately $27,000. Beacon Pointe Advisors LLC purchased a new position in Gossamer Bio during the fourth quarter valued at approximately $34,000. Finally, Ieq Capital LLC acquired a new position in Gossamer Bio in the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Key Stories Impacting Gossamer Bio

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: Gossamer said it will still seek FDA approval for seralutinib despite the late‑stage trial miss — this leaves a regulatory/appeal pathway that could preserve some future value. Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval
• Positive Sentiment: Seralutinib is being developed jointly with the Chiesi Group under an existing collaboration, which may share development costs and options for next steps. Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study
• Neutral Sentiment: Company released topline PROSERA results and held a call to discuss the data; the press release and transcript provide detail but didn’t change the headline outcome (primary endpoint not met). PROSERA Phase 3 topline results transcript
• Negative Sentiment: Topline data showed seralutinib failed to meet the trial’s primary endpoint in PAH — the core reason investors are selling and the primary driver of the stock’s decline. Gossamer Bio’s experimental lung condition drug fails in late-stage trial (Reuters)
• Negative Sentiment: Market reaction: major outlets report a steep sell‑off and trading was temporarily halted as the news was released, amplifying volatility and liquidity concerns. Gossamer Bio stock tumbles 80% on trial miss
• Negative Sentiment: Potential litigation risk: multiple law firms (Block & Leviton, Johnson Fistel) are soliciting GOSS investors and investigating potential securities claims, which could lead to lawsuits or settlements. Block & Leviton solicitation (GlobeNewswire) Johnson Fistel solicitation (GlobeNewswire)

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.